Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. Janiszewska M, et al. Among authors: arteaga cl. Nat Genet. 2015 Oct;47(10):1212-9. doi: 10.1038/ng.3391. Epub 2015 Aug 24. Nat Genet. 2015. PMID: 26301495 Free PMC article.
Growth retardation and tumour inhibition by BRCA1.
Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Holt JT, et al. Among authors: arteaga cl. Nat Genet. 1996 Mar;12(3):298-302. doi: 10.1038/ng0396-298. Nat Genet. 1996. PMID: 8589721
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Belkhiri A, et al. Among authors: arteaga cl. Clin Cancer Res. 2008 Jul 15;14(14):4564-71. doi: 10.1158/1078-0432.CCR-08-0121. Epub 2008 Jun 25. Clin Cancer Res. 2008. PMID: 18579663 Free PMC article.
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Miller TW, et al. Among authors: arteaga cl. Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934303 Free PMC article.
Does lapatinib work against HER2-negative breast cancers?
Mayer IA, Arteaga CL. Mayer IA, et al. Among authors: arteaga cl. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.
423 results